-
Motugivatrep (SJP-0132) 0.3% Ophthalmic Suspension for Dry Eye Disease: A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 3 Trial
Yuichi Hori1, Tomoyuki Wada2, Kazunori Omatsu2
1: Department of Ophthalmology, Toho University Faculty of Medicine, Tokyo, Japan; 2: Senju Pharmaceuticals Co. Ltd, Osaka, Japan
Clinical Ophthalmology. 2026:20:615529.
VIEW PUBLICATION -
Pharmacological Activity of Motugivatrep, a Novel Antagonist of Transient Receptor Potential Cation Channel Subfamily V Member 1
Tomoka Uemura, Hideharu Uchida, Chika Higashi, Ken-ichi Amano, Atsuhiro Kanda
Senju Pharmaceutical Co., Ltd.,Mochida Pharmaceutical Co., Ltd.
Biological and Pharmaceutical Bulletin、5ページ（2026 Volume 49 Issue 9 Pages 1524-1528）
VIEW PUBLICATION -
Chemerin and NPC2 produced from iPSC-derived Müller glial cells promote retinal ganglion cell regeneration
Momoko Kobayashi 1, Taku Tanaka 2,3, Yayoi Kishimoto 1, Masayuki Hirata 1, Noriyuki Azuma 2,4, Chiho Fukiage 1
1 Senju Pharmaceutical Co., Ltd., 2 Department of Ophthalmology and Laboratory for Visual Science, National Center for Child Health and Development, 3 CoMIT Omics Center, Graduate School of Medicine, Osaka University, 4 Department of Developmental and Regenerative Biology, Medical Research Institute, Institute of Science Tokyo
Experimental Eye Research, 2026;272:111196.
VIEW PUBLICATION -
Alfaxalone-Based Anesthetic Combinations to Minimize Anesthesia-Induced Transient Lens Opacity in Rats (Rattus norvegicus)
Atsuko Yamashita1, Yoshinori Yamagiwa2
1: Department of Pharmacology Research, Discovery Research Division, Senju Pharmaceutical Co, Ltd, Kobe, Hyogo, Japan 2: Pharmaceutical Sciences Department, Research and Development Division, Senju Pharmaceutical Co, Ltd, Kobe, Hyogo, Japan
Journal of the American Association for Laboratory Animal Science
VIEW PUBLICATION -
A novel NRF2 activator designed for an ophthalmic solution
Miyabe, Tomoyo; Hirata, Masayuki; Nakanishi, Yuki; Oba, Yuka; Kishimoto, Yayoi; Nakajima, Takeshi
Senju Pharmaceutical, Co., Ltd.
Experimental Eye Research. 2026; 269:111078.
VIEW PUBLICATION -
第5章 ICH Q9(R1)：品質リスクマネジメントに基づく取組み事例 第1節 製剤開発における品質リスクマネジメント
山口正純
千寿製薬株式会社 生産本部 唐津工場 品質部
ICH Q9(R1)品質リスクマネジメント －実践するためのアプローチ手法と具体的取組事例－：83～94ページ（Science & Technology社）
-
ゲノム言語モデルによるエピゲノムデザイン
-
ドライアイ患者の治療ニーズに関する webアンケート調査
髙見大介＊1、木 藤 学 志＊1、多 鹿 哲 也＊1、内 野 美 樹＊2
＊1 千寿製薬株式会社 研究開発本部 メディカルアフェアーズ部 ＊2 ケイシン五反田アイクリニック
医学と薬学, 83(1) 1-11, 2026
-
Results of a Randomized, Double-Masked, Placebo-Controlled Phase 1/2 Study of a TRPV1 Antagonist SJP-0132 in Participants With Dry Eye Disease
Tomoyuki Wada1, Kazunori Omatsu1, Stephen C. Pflugfelder2
1: Senju Pharmaceutical Co., Ltd, Hyogo, Japan. 2: Baylor College of Medicine, Houston, Texas, USA
American Journal of Ophthalmology. 2026:284:216-225.
VIEW PUBLICATION -
Comprehensive genotoxicity and carcinogenicity evaluations of motugivatrep (SJP-0132) — a transient receptor potential cation channel subfamily V member 1 antagonist
Kotaro Yamada1, Yoshinori Yamagiwa1, Hideya Yonekura1, Satoko Doi1, Mana Okada1, Satomi Kikuchi2, Yoshihisa Nakano2, Shigeki Matsumoto2, Gen Suzuki1, Ikuyo Atsumi1
1: Central Research Laboratories, Senju Pharmaceutical Co., Ltd. 2: Drug Discovery Research Center, Mochida Pharmaceutical Co., Ltd.
Fundamental Toxicological Sciences. 2026, 13: 103-117.
VIEW PUBLICATION